BACKGROUND: About 155 persons under age 18 develop Hodgkin's lymphoma (HL) in Germany every year. More than 90% survive at least 20 years. They may, however, suffer from late sequelae of treatment, including secondary malignant neoplasia (SMN). METHODS: 2548 patients from the German, Austrian, and Swiss pediatric Hodgkin's lymphoma studies that were conducted over the period 1978-2002 were asked every 2-3 years about possible late sequelae of treatment, either directly or through their physicians. The documented cases of SMN were analyzed for cumulative incidence, standardized incidence rates (SIR), and absolute excess risk (AER). RESULTS: 147 cases of SMN were diagnosed in 138 of the 2548 patients, including 47 cases of thyroid cancer, 37 of breast cancer, and 15 of hematopoietic neoplasia. The cumulative incidence of SMN at 20, 25, and 30 years was 7% , 11.2% , and 18.7% , respectively. These percentages are rather low compared to other international studies. For all types of SMN, the SIR was 9.1 and the AER was 16.8. Among the 123 patients with secondary solid tumors, 105 (85% ) had a tumor in the irradiated region. CONCLUSION: Survivors of pediatric HL must be informed about the risk of late sequelae of treatment for HL, including SMN in the irradiated region, and that they will need regular follow-up examinations. In the future, radiotherapy for children and adolescents should be further reduced or entirely avoided.
BACKGROUND: About 155 persons under age 18 develop Hodgkin's lymphoma (HL) in Germany every year. More than 90% survive at least 20 years. They may, however, suffer from late sequelae of treatment, including secondary malignant neoplasia (SMN). METHODS: 2548 patients from the German, Austrian, and Swiss pediatric Hodgkin's lymphoma studies that were conducted over the period 1978-2002 were asked every 2-3 years about possible late sequelae of treatment, either directly or through their physicians. The documented cases of SMN were analyzed for cumulative incidence, standardized incidence rates (SIR), and absolute excess risk (AER). RESULTS: 147 cases of SMN were diagnosed in 138 of the 2548 patients, including 47 cases of thyroid cancer, 37 of breast cancer, and 15 of hematopoietic neoplasia. The cumulative incidence of SMN at 20, 25, and 30 years was 7% , 11.2% , and 18.7% , respectively. These percentages are rather low compared to other international studies. For all types of SMN, the SIR was 9.1 and the AER was 16.8. Among the 123 patients with secondary solid tumors, 105 (85% ) had a tumor in the irradiated region. CONCLUSION: Survivors of pediatric HL must be informed about the risk of late sequelae of treatment for HL, including SMN in the irradiated region, and that they will need regular follow-up examinations. In the future, radiotherapy for children and adolescents should be further reduced or entirely avoided.
Authors: Suchitra Acharya; Kyriakie Sarafoglou; Michael LaQuaglia; Skyler Lindsley; William Gerald; Norma Wollner; Charlotte Tan; Charles Sklar Journal: Cancer Date: 2003-05-15 Impact factor: 6.860
Authors: R Sankila; S Garwicz; J H Olsen; H Döllner; H Hertz; A Kreuger; F Langmark; M Lanning; T Möller; H Tulinius Journal: J Clin Oncol Date: 1996-05 Impact factor: 44.544
Authors: Smita Bhatia; Yutaka Yasui; Leslie L Robison; Jillian M Birch; Monica K Bogue; Lisa Diller; Cyndi DeLaat; Franca Fossati-Bellani; Elaine Morgan; Odile Oberlin; Gregory Reaman; Frederick B Ruymann; Jean Tersak; Anna T Meadows Journal: J Clin Oncol Date: 2003-12-01 Impact factor: 44.544
Authors: Ann C Mertens; Pauline A Mitby; Gretchen Radloff; Irene M Jones; John Perentesis; William R Kiffmeyer; Joseph P Neglia; Anna Meadows; John D Potter; Debra Friedman; Yutaka Yasui; Leslie L Robison; Stella M Davies Journal: Cancer Date: 2004-09-15 Impact factor: 6.921
Authors: Ann-Kathrin Desch; Kristin Hartung; Ante Botzen; Alexander Brobeil; Mathias Rummel; Lars Kurch; Thomas Georgi; Theresa Jox; Stefan Bielack; Stefan Burdach; Carl Friedrich Classen; Alexander Claviez; Klaus-Michael Debatin; Martin Ebinger; Angelika Eggert; Jörg Faber; Christian Flotho; Michael Frühwald; Norbert Graf; Norbert Jorch; Udo Kontny; Christof Kramm; Andreas Kulozik; Joachim Kühr; Karl-Walter Sykora; Markus Metzler; Hermann L Müller; Michaela Nathrath; Thomas Nüßlein; Michael Paulussen; Arnulf Pekrun; Dirk Reinhardt; Harald Reinhard; Claudia Rössig; Axel Sauerbrey; Paul-Gerhardt Schlegel; Dominik T Schneider; Wolfram Scheurlen; Lothar Schweigerer; Thorsten Simon; Meinolf Suttorp; Peter Vorwerk; Roland Schmitz; Regine Kluge; Christine Mauz-Körholz; Dieter Körholz; Stefan Gattenlöhner; Andreas Bräuninger Journal: Leukemia Date: 2019-08-20 Impact factor: 11.528
Authors: Jung-Young Kim; Jennifer G Jackman; Sarah Woodring; Frances McSherry; James E Herndon; Annick Desjardins; Henry S Friedman; Katherine B Peters Journal: Neurooncol Pract Date: 2019-02-04
Authors: Kathryn R Tringale; Leslie A Modlin; Kevin Sine; Christopher J Forlenza; Oren Cahlon; Suzanne L Wolden Journal: Radiother Oncol Date: 2022-01-29 Impact factor: 6.901
Authors: Gabrielle F Callanan; Kaitlin M Curran; Cyril Parachini-Winter; Shay Bracha; Sean Spagnoli; Duncan S Russell; Susanne M Stieger-Vanegas; Lynn Griffin; Haley Leeper Journal: JFMS Open Rep Date: 2020-02-27
Authors: Poonam Nagpal; Mohamed R Akl; Nehad M Ayoub; Tatsunari Tomiyama; Tasheka Cousins; Betty Tai; Nicole Carroll; Themba Nyrenda; Pritish Bhattacharyya; Michael B Harris; Andre Goy; Andrew Pecora; K Stephen Suh Journal: Oncotarget Date: 2016-10-11